Bluebird Exits Europe, Casting Clouds Over Gene Therapy Commercial Effort
Executive Summary
The company will prioritize US market for gene therapies; FDA also placed eli-cel for CALD on clinical hold following a case of MDS.
You may also be interested in...
CSL/UniQure’s Hemgenix To Enter Uncertain EU Market After Regulatory Nod
The firms’ one-time hemophilia B gene therapy has been approved in the EU just months after a US nod, but concerns remain about its prospects on a market that has seen several setbacks for other gene therapies.
Bluebird’s Zynteglo Shows Long-Term Efficacy And Safety Amid US Commercialization Push
Data presented at ASH show patients maintaining transfusion independence for years after infusion, months after bluebird won FDA approval for the beta-thalassemia gene therapy.
Sickle Cell Gene Therapy Cost Effectiveness Draws Scrutiny At ASH
According to a study presented at the American Society of Hematology, based on existing gene therapy prices, equitable use of sickle cell disease gene therapy requires expanding into patients who are younger and have less severe disease.